Compare Abeona Therapeutics Inc (ABEO) vs American Well Corp (AMWL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs American Well Corp — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while American Well Corp trades at $8.8 (market cap $150.21M). The key difference: Abeona Therapeutics Inc is far larger — about 2.5× American Well Corp's market cap. Which is the better fit depends on your goals.
| ABEO | AMWL | |
|---|---|---|
Market Cap | $373.32M | $150.21M |
Sector | Health | Health |
52-Week High | $7.23 | $9.83 |
52-Week Low | $4.17 | $3.78 |
Enterprise Value | $228.22M | -$25.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AMWL trades at $8.99, down 2.81% today, with a bullish technical signal from moving averages but neutral oscillators. The company shows improving financial trends with revenue stabilizing near $249 million in 2025 and net losses narrowing to -$96 million. Recent news highlights momentum, including a Zacks upgrade to Buy on June 24, 2026, and Amazon appointing Amwell's co-founder to lead its healthcare unit on May 27, 2026.
Outlook remains cautious due to persistent losses and negative cash flow, though valuation metrics like P/S of 0.64 and P/B of 0.68 suggest potential upside if profitability improves. Risks include competitive pressures and execution challenges, but analyst consensus leans Hold with a $7.25 price target, indicating limited near-term growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →
